Clinical trial · Observational
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
A Real-world Study: Efficacy and Safety of Selinexor-based Regimens for Non-Hodgkin Lymphoma
NCT05852028CI-TRIAL-00066296unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to observe and explore the efficacy and safety of selinexor-based regimen in patients with Non-Hodgkin lymphoma
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| DLBCL | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| T Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Selinexor | Drug | Selinexor | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- selinexor-based regimens
- description
- This study is a real-world study to explore the safety and efficacy of selinexor-based therapy in patients with lymphoma. It is planned to enroll 250 patients with lymphoma, including 150 patients with diffuse large B-cell lymphoma and 100 patients with peripheral T and NK/T-cell lymphoma.
- interventionNames
- Drug: Selinexor
Primary outcomes (2)
- measure
- Objective response rate(ORR)
- timeFrame
- throughout the study, an average of 1 year
- description
- the percentage of patients with complete response and partial response
- measure
- incidence of adverse events/ serious adverse events
- timeFrame
- throughout the study, an average of 2 year
- description
- identify patterns of incidence in adverse events
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Know and voluntarily sign the Informed Consent Form (ICF) * Clinically confirmed DLBCL, T or NK cell lymphoma * Patients with DLBCL or T or NK cell lymphoma who have used selinexor-based therapy in the past 3 months are included * Cooperate with clinical diagnosis and treatment management, and provide disease-related past medical history materials Exclusion Criteria: * Previously received selinexor * Poor patient compliance * physicians evaluate that patients are not suitable for enrollment
References
Publications (0)
Data not yet available
No reference posted for this study.